IN2014MN02126A - - Google Patents

Info

Publication number
IN2014MN02126A
IN2014MN02126A IN2126MUN2014A IN2014MN02126A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A IN 2126MUN2014 A IN2126MUN2014 A IN 2126MUN2014A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A
Authority
IN
India
Prior art keywords
compounds
calcium
crac
channel
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Nageswara Rao Irlapati
Zubair Abdul Wajid Shaikh
Vijay Pandurang Karche
Gokul Keruji Deshmukh
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN2126MUN2014 priority Critical patent/IN2014MN02126A/en
Publication of IN2014MN02126A publication Critical patent/IN2014MN02126A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
IN2126MUN2014 2012-05-02 2013-05-01 IN2014MN02126A (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2126MUN2014 IN2014MN02126A (de) 2012-05-02 2013-05-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN6KO2012 2012-05-02
IN2126MUN2014 IN2014MN02126A (de) 2012-05-02 2013-05-01
PCT/IB2013/053440 WO2013164769A1 (en) 2012-05-02 2013-05-01 Substituted pyridine compounds as crac modulators

Publications (1)

Publication Number Publication Date
IN2014MN02126A true IN2014MN02126A (de) 2015-09-11

Family

ID=48428565

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2126MUN2014 IN2014MN02126A (de) 2012-05-02 2013-05-01

Country Status (7)

Country Link
US (2) US9399638B2 (de)
EP (1) EP2844655A1 (de)
AU (1) AU2013255437A1 (de)
CA (1) CA2871270A1 (de)
IN (1) IN2014MN02126A (de)
WO (1) WO2013164769A1 (de)
ZA (1) ZA201407685B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
WO2015090579A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
CN105367547B (zh) * 2014-08-19 2019-04-23 北京桦冠生物技术有限公司 一种噁唑啉酮抗生素的新合成工艺
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US10525021B2 (en) 2014-11-18 2020-01-07 Rutgers, The State University Of New Jersey Mitochondrial uncouplers for treatment of metabolic diseases and cancer
WO2016138472A1 (en) 2015-02-27 2016-09-01 Calcimedica, Inc. Pancreatitis treatment
CN107847548B (zh) 2015-05-18 2022-06-14 贝思以色列女会吏医学中心公司 P物质、肥大细胞脱颗粒抑制剂和周围神经病
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
JP6738575B2 (ja) 2015-08-07 2020-08-12 カルシメディカ,インク. 脳卒中および外傷性脳損傷の処置のためのcracチャネル阻害剤の使用
CN109415363B (zh) 2016-05-18 2021-07-20 罗格斯,新泽西州立大学 用于治疗代谢疾病和癌症的新的线粒体解偶联剂
MX2020006613A (es) * 2017-12-22 2020-11-13 Ravenna Pharmaceuticals Inc Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CA3112907A1 (en) 2018-09-14 2020-03-19 Rhizen Pharmaceuticals Ag Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412257A (pt) 2003-07-23 2006-10-03 Synta Pharmaceuticals Corp compostos para inflamação e usos imuno-relacionados
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
US8202999B2 (en) 2005-01-07 2012-06-19 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
ZA200707125B (en) 2005-01-25 2008-11-26 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
CA2595000C (en) 2005-01-25 2013-10-15 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
CA2639927A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
EP1983971A4 (de) 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp Substituierte aromatische verbindungen für entzündungs- und immunbedingte verwendung
CA2639913A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2007089904A2 (en) 2006-01-31 2007-08-09 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
EP2069359B1 (de) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenylverbindungen und anwendungsverfahren dafür
CA2695148A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses
KR101541558B1 (ko) 2007-08-17 2015-08-03 액테리온 파마슈티칼 리미티드 S1p1/edg1 수용체 조절제로서의 피리딘 유도체
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
EA018817B1 (ru) 2008-05-23 2013-10-30 Глэксо Груп Лимитед Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
DE102008031299B4 (de) 2008-07-02 2014-10-30 Acandis Gmbh & Co. Kg Filter für ein Blutgefäß
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
TW201018667A (en) 2008-10-01 2010-05-16 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
UY32856A (es) 2009-08-26 2011-03-31 Astrazeneca Ab Derivados heterocíclicos de urea y métodos de uso de los mismos
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
RS54870B1 (sr) 2010-10-30 2016-10-31 Lupin Ltd Derivati oksazolina i izoksazolina kao crac modulatori
JP5985611B2 (ja) 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のための化合物
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2012325901A1 (en) 2011-10-19 2014-05-15 Calcimedica, Inc. Compounds that modulate intracellular calcium

Also Published As

Publication number Publication date
US20160304506A1 (en) 2016-10-20
US9399638B2 (en) 2016-07-26
AU2013255437A1 (en) 2014-11-13
US20150111900A1 (en) 2015-04-23
CA2871270A1 (en) 2013-11-07
ZA201407685B (en) 2015-11-25
EP2844655A1 (de) 2015-03-11
WO2013164769A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
IN2014MN02126A (de)
IN2014MN02127A (de)
CO6430427A2 (es) Derivados de benzofuranilo
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12015500551A1 (en) Tricyclic quinoline and quinoline derivatives
GEP20166438B (en) Imidazopyrrolidinone compounds
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CR20110103A (es) Heteroarilos sustituidos
IN2014CN04907A (de)
MX2015012478A (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
MD20140109A2 (ro) Compuşi ai indolului şi indazolului care activează AMPK
IN2012DN00943A (de)
WO2012170931A3 (en) Compounds that modulate intracellular calcium
MX337711B (es) Compuestos que modulan el calcio intracelular.
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
EA026940B9 (ru) Замещенные хромановые соединения в качестве модуляторов чувствительного к кальцию рецептора
WO2012170951A3 (en) Compounds that modulate intracellular calcium
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
PH12014501979B1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
IN2015MN00421A (de)
MX357828B (es) Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.